Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Oncology · NF2-related schwannomatosis

Navigating Treatment Options

At a Glance

Treatment for NF2-related schwannomatosis is tailored to each patient and typically includes active surveillance, bevacizumab infusions, or specialized surgery. Because interventions carry risks like hearing loss, care focuses heavily on long-term hearing preservation and quality of life.

Deciding how to treat NF2-related schwannomatosis is a complex process that shifts as tumors grow or symptoms change. Because every patient’s journey is different, your care team should use a “watch, wait, and intervene” strategy tailored to your specific mutation and lifestyle priorities [1][2].

The Treatment Decision Framework

In a specialized NF clinic, doctors typically categorize treatment into three main “buckets”:

1. Active Surveillance (Watch and Wait)

For many patients, especially those with small, stable tumors or mosaicism, the best first step is regular monitoring with MRIs and hearing tests (audiograms) [2]. Since these tumors are generally slow-growing, avoiding immediate treatment can preserve quality of life for years [3].

2. Systemic (Medical) Therapy: Bevacizumab

When tumors are growing or hearing starts to drop, doctors may turn to bevacizumab [4].

  • How it works: This is an intravenous (IV) medication (often given via a port or regular IV line every 3 to 4 weeks) that blocks the blood supply to tumors. It is not a cure, but it can shrink tumors and stabilize or improve hearing [5][6].
  • Safety and Side Effects: Bevacizumab requires a serious commitment to monitoring. It carries risks of severe side effects, including proteinuria (kidney damage), high blood pressure, delayed wound healing, severe bleeding risks, and a risk of ovarian failure in women [7][8]. Patients on this drug must undergo regular blood and urine testing.
  • Logistics: The regular infusion schedule may require patients to miss work or school, making it important to plan around your daily life. Current research suggests that “low-dose” regimens can be just as effective as higher doses while potentially reducing some side effects [9][10].

3. Surgical and Radiation Interventions

When a tumor becomes large or threatens vital functions, physical intervention is necessary:

  • Microsurgery: This remains the standard for large tumors or those causing brainstem pressure. The goal is to remove the tumor while preserving the facial nerve [5][11]. However, it is crucial to understand that surgery itself carries a very high risk of immediate hearing loss or total deafness in the operated ear. The tumor often intertwines with the hearing nerve, making preservation difficult. Additionally, NF2 patients may take longer to recover from facial nerve injury due to the lack of merlin protein, which helps nerves heal [12].
  • Stereotactic Radiosurgery (SRS): This is a focused form of radiation. While it is effective at stopping small tumors from growing, it is generally not the first choice for NF2 patients unless surgery is too risky [13]. There is a very small risk (typically less than 1%) of the radiation causing a new, cancerous tumor later in life, a risk that your care team will weigh carefully against the benefits [13].

Hearing Rehabilitation: CI vs. ABI

If hearing is lost—either due to tumor growth or surgery—there are two high-tech options to restore sound:

  • Cochlear Implant (CI): This is the first-line choice if your cochlear nerve (the hearing nerve) is still intact [14]. Patients with a CI generally have much better speech recognition outcomes than those with an ABI [14][15].
  • Auditory Brainstem Implant (ABI): If the hearing nerve must be removed during surgery, an ABI can be placed directly onto the brainstem [14]. While an ABI usually provides an “awareness” of sound and helps with lip-reading, it rarely restores clear speech [16][17].

Daily Life Management and Proactive Skills

Beyond medical procedures, practical management is a huge part of treatment:

  • Vestibular Rehabilitation: Because balance is heavily affected, specialized physical therapy (vestibular rehab) is critical to help your brain adapt to inner-ear damage and prevent falls.
  • Communication Planning: Many patients find empowerment in proactively learning American Sign Language (ASL) or taking lip-reading classes before profound hearing loss occurs. Building these skills early provides a safety net and reduces isolation.

A Note on Specialty Care

Inexperienced doctors may sometimes recommend immediate, aggressive radiation or surgery for small, silent tumors. However, current international guidelines emphasize that hearing preservation and quality of life should guide every decision [18][19]. If a doctor suggests a treatment that seems high-risk for your facial nerve or hearing, seeking a second opinion at a dedicated NF Center of Excellence is often the best path forward [20].

Common questions in this guide

Is surgery always required for NF2 tumors right away?
No, immediate surgery is not always necessary. For many patients with small, stable tumors, doctors recommend a 'watch and wait' approach. This active surveillance involves regular MRIs and hearing tests to monitor the tumors while preserving your quality of life for as long as possible.
What is bevacizumab and how does it treat NF2?
Bevacizumab is an intravenous medication that works by blocking the blood supply to tumors. While it is not a cure, it can shrink tumors and help stabilize or improve hearing. It does require regular monitoring due to the risk of severe side effects like kidney damage and high blood pressure.
Will I lose my hearing if I have surgery for an NF2 tumor?
Surgery for these tumors carries a very high risk of immediate hearing loss or total deafness in the operated ear. Because the tumors often intertwine directly with the hearing nerve, preserving hearing during surgical removal is extremely difficult.
What is the difference between a cochlear implant and an auditory brainstem implant (ABI)?
A cochlear implant is used when your hearing nerve is still intact, and it generally provides better speech recognition. If the hearing nerve must be removed during surgery, an auditory brainstem implant can be placed directly on the brainstem to provide an awareness of sound, though it rarely restores clear speech.
How can I manage the balance issues caused by NF2?
Vestibular rehabilitation is highly recommended for balance problems. This specialized physical therapy helps your brain adapt to inner-ear damage caused by the tumors or treatments, which improves your balance and prevents dangerous falls.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which surgery or radiation approach would offer me the best chance of preserving my hearing in the long term?
  2. 2.Given the higher risk of facial nerve paralysis in NF2, what specialized intraoperative monitoring do you use to protect the nerve during surgery?
  3. 3.Am I a candidate for 'low-dose' bevacizumab, and how often would we need to monitor my blood pressure and kidney function?
  4. 4.If my hearing declines, would I be a candidate for a cochlear implant first, or would my vestibular schwannoma surgery require an ABI (Auditory Brainstem Implant)?
  5. 5.What is your personal experience with performing surgery on NF2 patients versus general vestibular schwannoma patients?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Inherited genetic syndromes and meningiomas.

    Look A, Lonser RR

    Handbook of clinical neurology 2020; (169()):121-129 doi:10.1016/B978-0-12-804280-9.00007-X.

    PMID: 32553283
  2. 2

    Progression of hearing loss in neurofibromatosis type 2 according to genetic severity.

    Emmanouil B, Houston R, May A, et al.

    The Laryngoscope 2019; (129(4)):974-980 doi:10.1002/lary.27586.

    PMID: 30456886
  3. 3

    Long-term growth rate of vestibular schwannoma in neurofibromatosis 2: A volumetric consideration.

    Picry A, Bonne NX, Ding J, et al.

    The Laryngoscope 2016; (126(10)):2358-62 doi:10.1002/lary.25976.

    PMID: 27075822
  4. 4

    Efficacy and Toxicity of Bevacizumab in Children with NF2-Related Schwannomatosis: A Systematic Review.

    Tops AL, Schopman JE, Koot RW, et al.

    Cancers 2025; (17(3)) doi:10.3390/cancers17030519.

    PMID: 39941885
  5. 5

    Genetic Basis and Clinical Management of Schwannomatosis.

    Nagasaka S, Phi JH

    Journal of Korean Neurosurgical Society 2025; (68(3)):286-293 doi:10.3340/jkns.2025.0001.

    PMID: 40049215
  6. 6

    Bevacizumab Treatment for Patients with NF2-Related Schwannomatosis: A Single Center Experience.

    Douwes JPJ, Hensen EF, Jansen JC, et al.

    Cancers 2024; (16(8)) doi:10.3390/cancers16081479.

    PMID: 38672561
  7. 7

    Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes.

    Lu VM, Ravindran K, Graffeo CS, et al.

    Journal of neuro-oncology 2019; (144(2)):239-248 doi:10.1007/s11060-019-03234-8.

    PMID: 31254266
  8. 8

    Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence.

    Renzi S, Michaeli O, Salvador H, et al.

    Pediatric blood & cancer 2020; (67(5)):e28228 doi:10.1002/pbc.28228.

    PMID: 32124552
  9. 9

    Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma.

    Plotkin SR, Allen J, Dhall G, et al.

    Neuro-oncology 2023; (25(8)):1498-1506 doi:10.1093/neuonc/noad066.

    PMID: 37010875
  10. 10

    A systematic review of targeted therapy for vestibular schwannoma in patients with NF2-related schwannomatosis.

    Chiranth S, Langer SW, Poulsen HS, Urup T

    Neuro-oncology advances 2023; (5(1)):vdad099 doi:10.1093/noajnl/vdad099.

    PMID: 37706198
  11. 11

    Volumetric analysis of tumor control following subtotal and near-total resection of vestibular schwannoma.

    Jacob JT, Carlson ML, Driscoll CL, Link MJ

    The Laryngoscope 2016; (126(8)):1877-82 doi:10.1002/lary.25779.

    PMID: 27426941
  12. 12

    Neuron-Specific Deletion of the Nf2 Tumor Suppressor Impairs Functional Nerve Regeneration.

    Schulz A, Büttner R, Toledo A, et al.

    PloS one 2016; (11(7)):e0159718 doi:10.1371/journal.pone.0159718.

    PMID: 27467574
  13. 13

    Radiation treatment of benign tumors in NF2-related-schwannomatosis: A national study of 266 irradiated patients showing a significant increase in malignancy/malignant progression.

    Evans DG, Halliday D, Obholzer R, et al.

    Neuro-oncology advances 2023; (5(1)):vdad025 doi:10.1093/noajnl/vdad025.

    PMID: 37051330
  14. 14

    Comparing Speech Recognition Outcomes Between Cochlear Implants and Auditory Brainstem Implants in Patients With NF2-Related Schwannomatosis.

    Dornhoffer JR, Plitt AR, Lohse CM, et al.

    Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2024; (45(1)):29-35 doi:10.1097/MAO.0000000000004047.

    PMID: 37875011
  15. 15

    Ipsilateral Cochlear Implantation in the Presence of Observed and Irradiated Vestibular Schwannomas.

    Urban MJ, Moore DM, Kwarta K, et al.

    The Annals of otology, rhinology, and laryngology 2020; (129(12)):1229-1238 doi:10.1177/0003489420935482.

    PMID: 32551844
  16. 16

    Evaluation of phoneme recognition skills in pediatric auditory brainstem implant users.

    Baş B, Yücel E

    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2022; (279(4)):1741-1749 doi:10.1007/s00405-021-06840-3.

    PMID: 33977366
  17. 17

    [AUDITORY BRAINSTEM IMPLANTS (ABI) IN CHILDREN: CASE SERIES IN SHAARE ZEDEK MEDICAL CENTER].

    Perez R, Sichel JY, Salem R, et al.

    Harefuah 2023; (162(7)):413-418.

    PMID: 37561029
  18. 18

    Early prediction of functional prognosis in neurofibromatosis type 2 patients based on genotype-phenotype correlation with targeted deep sequencing.

    Teranishi Y, Miyawaki S, Nakatomi H, et al.

    Scientific reports 2022; (12(1)):9543 doi:10.1038/s41598-022-13580-9.

    PMID: 35681071
  19. 19

    Quality of life assessment in schwannomatosis - A systematic review.

    Lawson McLean AC, Rosahl SK, Lawson McLean A, et al.

    Brain & spine 2025; (5()):104279 doi:10.1016/j.bas.2025.104279.

    PMID: 40510571
  20. 20

    Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution.

    Forde C, King AT, Rutherford SA, et al.

    Neuro-oncology 2021; (23(7)):1113-1124 doi:10.1093/neuonc/noaa284.

    PMID: 33336705

This page explains treatment options for NF2-related schwannomatosis for educational purposes only. Always consult your specialized NF care team regarding medical decisions and treatment plans.

Get notified when new evidence is published on Full NF2-related schwannomatosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.